[Prospects of antiaggregant therapy in prevention of atherosclerosis].
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000517:prevention & control*; D001241:Aspirin / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000517:prevention & control; D004176:Dipyridamole / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000517:prevention & control; D007213:Indomethacin / Q000627:therapeutic use; D010208:Papaverine / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000627:therapeutic use*; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000627:therapeutic use; D014970:Xanthines / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D011453:Prostaglandins; D011465:Prostaglandins, Synthetic; D014970:Xanthines; D004176:Dipyridamole; D010208:Papaverine; D011464:Epoprostenol; D001241:Aspirin; D013442:Sulfinpyrazone; D007213:Indomethacin
Prospettive della terapia antiaggregante nella prevenzione dell'aterosclerosi.